Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mary Doi
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0000-0002-6310-4734
Observed ORCID:
0000-0002-6310-4734
OpenAlex ID:
A5041296050
Dose-finding studies in drug development for rare genetic diseases
2022
·
Lingshan Wang
, Jie Wang
, et al.
·
Orphanet Journal of Rare Diseases
·
10
PDF
Confirmatory Evidence Used in Non‐Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020–2023
2025
·
Bridget M. Nugent
, Anuradha Ramamoorthy
, et al.
·
Clinical Pharmacology & Therapeutics
·
5
Pivotal trial characteristics and types of endpoints used to support Food and Drug Administration rare disease drug approvals between 2013 and 2022
2025
·
Kyungwan Hong
, Bridget Nugent
, et al.
·
Clinical Trials
·
3
Evolving landscape of drug development for pediatric rare diseases–from successes to strategies for addressing unmet needs
2026
·
Sydney Stern
, Yifei Zhang
, et al.
·
Journal of Pharmaceutical Sciences
Show more works
View as search
Works count:
4
Citation count:
18
H-index:
3
I10-index:
1
Year
Topic
Type